Article History
Received: 16 October 2018
Accepted: 4 February 2019
First Online: 7 March 2019
Duality of interest
: CKK has received grants from Boehringer Ingelheim, outside the submitted work. SC has nothing to disclose. RR has received grants and personal fees from Novo Nordisk, grants from Boehringer Ingelheim, personal fees from Eli Lilly, personal fees from Takeda, personal fees from Sanofi, and grants and personal fees from Merck, outside the submitted work.